TriangleNCT00258206 · OUTCOME
Event-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- 1 year
What was measured
Percentage of study participants who did not report that their multiple myeloma relapsed or progressed (got worse)
Groups in this outcome
Rituximab + Cyclophosphamide
Rituximab 375 mg/m\^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m\^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m\^2 once each during months 3, 6, 9, and 12
| Group | Source count |
|---|---|
| Rituximab + Cyclophosphamide | 21 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Rituximab + Cyclophosphamide | 29 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 29
- denoms
- counts
- group Id
- OG000
- value
- 21
- units
- Participants
- description
- Percentage of study participants who did not report that their multiple myeloma relapsed or progressed (got worse)
- groups
- description
- Rituximab 375 mg/m\^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m\^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m\^2 once each during months 3, 6, 9, and 12
- id
- OG000
- title
- Rituximab + Cyclophosphamide
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Event-free Survival
- type
- PRIMARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice